Investigational drug · Phase 2
ORX750
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "ORX750"
First trial start
2024
Dec 23, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ORX750", any sponsor or status.
Conditions studied
As listed on its trial records.
- Narcolepsy Type 1
- Narcolepsy Type 2
- Idiopathic Hypersomnia
Approved drugs for the same conditions: Narcolepsy · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "ORX750" as an intervention, largest first.
- A Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaPivotal-lookingRecruiting
Centessa Pharmaceuticals (UK) LimitedIndustry
NCT06752668 · 248 participants (planned) · Start Dec 23, 2024 · Primary completion Dec 2026
Drug: ORX750; Placebo · For: Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia
Sites: Auburn, Alabama; Chandler, Arizona; Scottsdale, Arizona · 37 sites in all
- A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of HypersomnolencePivotal-lookingRecruiting
Centessa Pharmaceuticals (UK) LimitedIndustry
NCT07598708 · 222 participants (planned) · Start May 29, 2026 · Primary completion Sep 30, 2027
Drug: cleminorexton; Placebo · For: Narcolepsy Type 1; Narcolepsy Type 2
Sites: Birmingham, Alabama; Colorado Springs, Colorado; Brandon, Florida · 26 sites in all
- A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaRecruiting
Centessa Pharmaceuticals (UK) LimitedIndustry
NCT07096674 · 90 participants (planned) · Start Aug 12, 2025 · Primary completion Apr 30, 2026
Drug: ORX750; ORX750 and 1 more · For: Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia
Sites: Auburn, Alabama; Santa Ana, California; Miami, Florida · 24 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Understanding idiopathic hypersomnia: diagnosis, pathophysiology, and management.
Shahzadi M, Monderer R, Thorpy MJ · Curr Opin Pulm Med 2025
Also in development for Narcolepsy Type 1
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.